Literature DB >> 25744233

Investigation of possible prophylactic, renoprotective, and cardioprotective effects of thromboprophylactic drugs against ischemia-reperfusion injury.

Sinan Demirtas1, Oguz Karahan2, Suleyman Yazıcı3, Orkut Guclu2, Ahmet Calıskan2, Orhan Tezcan2, Ibrahim Kaplan4, Celal Yavuz2.   

Abstract

The aim of this study was to investigate whether anticoagulant and antiaggregant agents have protective effects against oxidative damage induced by peripheral ischemia-reperfusion (I/R). Groups were created as follows: control group, I/R group (sham group), I/R plus acetylsalicylic acid (Group I), I/R+clopidogrel (Group II), I/R+rivaroxaban (Group III), I/R+bemiparin sodium (Group IV), and I/R+enoxaparin sodium (Group V). In Groups I, II, III, IV, and V, drugs were administered daily for 1 week before I/R creation. Peripheral I/R was induced in the I/R groups by clamping the right femoral artery. The rats were sacrificed 1 hour after reperfusion. Nitrogen oxide levels, malondialdehyde (MDA) levels, paraoxonase-1 (PON1) activity, and prolidase activity were evaluated in both cardiac and renal tissues. There was no significant difference in nitrogen oxide levels between the groups. However, cardiac and renal MDA were significantly higher and PON1 activity was markedly lower in the I/R groups compared with the control group (p<0.05). Although elevated prolidase activity was detected in both the cardiac and renal tissue of the I/R groups, only the sham group and Group V had significantly higher renal prolidase activity (p<0.05). Group V had significantly higher cardiac MDA, PON1, prolidase levels, and renal prolidase activity compared with the sham group (p<0.05). Significant improvement in renal MDA levels was only observed in Group III, and marked improvement was observed in the cardiac MDA levels of Group II when compared with the sham group (p<0.05). Thromboprophylactic agents appear to provide partial or prominent protection against I/R injury.
Copyright © 2015. Published by Elsevier Taiwan.

Entities:  

Keywords:  Antiaggregant drugs; Anticoagulant drugs; Cardioprotection; Ischemia–reperfusion injury; Renoprotection

Mesh:

Substances:

Year:  2015        PMID: 25744233     DOI: 10.1016/j.kjms.2014.12.005

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  6 in total

1.  Possible renoprotective effects of dabigatran.

Authors:  Oğuz Karahan
Journal:  Anatol J Cardiol       Date:  2015-05-22       Impact factor: 1.596

2.  Enoxaparin attenuates doxorubicin induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis.

Authors:  Reem Ali Shaker; Samer Hassan Abboud; Hayder Chasib Assad; Najah Hadi
Journal:  BMC Pharmacol Toxicol       Date:  2018-01-10       Impact factor: 2.483

3.  Circulating Prolidase Activity in Patients with Myocardial Infarction.

Authors:  Adnan Sultan; Yuting Zheng; Patrick J Trainor; Yong Siow; Alok R Amraotkar; Bradford G Hill; Andrew P DeFilippis
Journal:  Front Cardiovasc Med       Date:  2017-07-31

Review 4.  Recent Advances in Pharmacological and Non-Pharmacological Strategies of Cardioprotection.

Authors:  Afonso Caricati-Neto; Paolo Ruggero Errante; Francisco Sandro Menezes-Rodrigues
Journal:  Int J Mol Sci       Date:  2019-08-16       Impact factor: 5.923

5.  Direct oral anticoagulant agents attenuate temporary aortic occlusion-induced renal oxidative and inflammatory responses in rats.

Authors:  Selim Durmaz; Tünay Kurtoğlu; Ömer Faruk Rahman; Canten Tataroğlu; Mustafa Yılmaz; Emin Barbarus; Muhammet Hüseyin Erkan
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2022-04-27       Impact factor: 0.704

6.  An evaluation of rivaroxaban and clopidogrel in a rat lower extremity ischemia-reperfusion model: An experimental study.

Authors:  Ersan Özbudak; Fatma Ceyla Eraldemir; Ali Ahmet Arıkan; Deniz Şahin; Hale Maral Kır; Tolga Kurt; Ömer Faruk Gülaştı; Şadan Yavuz
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2019-10-23       Impact factor: 0.332

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.